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Addison's disease (AD) is a chronic, lifelong disorder caused by adrenal gland 
insufficiencyz and it requires lifelong daily therapy with cortisol repla.cement, which is 
a steroid hormone. Since cortisol is a stress hormone, one can expect fatigue, sleep 
disturbance, depression, anxiety and a generally low quality of life (QOL). Studies 
have shown that cortisol replacement therapy has a great effect on the health 
perception, general well-being and QOL of patients with AD. 
Addison's disease (AD) is a chronic, lifelong disorder caused by adrenal gland 
insufficiency which leads to insufficient cortisol. Since cortisol is a stress hormone, 
the symptoms are fatigue, sleep disturbance, depression, anxiety and a generally low 
quality of life (QOL). AD requires lifelong daily therapy with cortisol replacement, 
which is a steroid hormone. Studies have shown that cortisol replacement therapy has 
a beneficial effect on the health perception, general well-being and QOL of patients 
with AD. 
As studies of the disease to date have been conducted mostly in Europe, it is 
necessary to establish how applicable they are to South Africa, bearing in mind that 
South Africa is a developing country with different needs. Specifically, answers need 
to be found to the question of whether we can apply the European findings and their 
treatment packages to South African patients and whether they are able to have the 
same QOL as the Europeans. This s udy finds that our patients do indeed have the 
same QOL, and that we should therefore be able to apply the European findings here. 
Measuring QOL alone, however, gives us very general information which is not 
sufficient for our study. The second aim of this research is to compare different 
aspects ofQOL in AD, as this has not been researched before. This knowledge should 
help clinicians to recognise QOL impairment better, which will enable modifiable risk 
factors to be adjusted with early intervention. (For example, psychological 
impairment can be reduced with counselling.) This study also finds that some AD 
patients who suffer a combination of other autoimmune diseases have a lower QOL. 
The main instrument used for this research was the Rotterdam QOL questionnaire. 
We also used the Beck depression scale, and the Spielberger anxiety inventory. Our 
sample consisted of 100 patients with a confirmed diagnosis of AD from all around 
South Africa, and a control group who did not have AD or any other autoimmune 












Assessing the effect of Addison's disease on padent quaHty ofUfe within the 




Supervised by Professor Mark Sohns 
Neuropsychology Masters Degree 
Department of Psychology 













This project would not have been possible without the support of my supervisor. 
Many thanks to Professor Mark Solms, who read my numerous revisions and helped 
to give this project structure and coherence. 
lowe a debt of gratitude to Dr Oz Omeen for acting as an informal consultant and for 
providing financial support for my research. 
Thank you to Dr Ian Ross for providing bases from which the research could be 
conducted, and for his advice regarding endocrinological diseases. 
Thanks to Dr Helgo Shuma, health psychologist at UeT, who assisted me in finding 
the best quality of life questionnaires. 
Thanks to my husband Toufan Darbandi and my mother for enduring this long 
process with me and for their love and support. 













Addison's disease (AD) is a chronic, lifelong disorder caused by adrenal gland 
insufficiency, and it requires lifelong daily therapy with cortisol replacement, which is 
a steroid hormone. Since cortisol is a stress hormone, one can expect fatigue, sleep 
disturbance, depression, anxiety and a generally low quality of life (QOL). Studies 
have shown that cortisol replacement therapy has a great effect on the health 
perception, general well-being and QOL of patients with AD. 
Since cortisol is a stress hormone, the symptoms are fatigue, sleep disturbance, 
depression, anxiety and a generally low quality of life (QOL). AD requires lifelong 
daily therapy with cortisol replacement, which is a steroid hormone. Studies have 
shown that cortisol replacement therapy has a beneficial effect on the health 
perception, general well-being and QOL of patients with AD. 
As studies of the disease to date have been conducted mostly in Europe, it is 
necessary to establish how applicable they are to South Africa, bearing in mind that 
South Africa is a developing country with different needs. Specifically, answers need 
to be found to the question of whether we can apply the European findings and their 
treatment packages to South African patients and whether they are able to have the 
same QOL as the Europeans. This study finds that our patients do indeed have the 
same QOL, and that we should therefore be able to apply the European findings here. 
Measuring QOL alone, however, gives us very general information which is not 
sufficient for our study. The second aim of this research is to compare different 
aspects ofQOL in AD, as this has not been researched before. This knowledge should 
help clinicians to recognise QOL impairment better, which will enable modifiable risk 
factors to be adjusted with early intervention. (For example, psychological 
impairment can be reduced with counselling.) This study also finds that some AD 
patients who suffer a combination of other autoimmune diseases have a lower QOL. 
The main instrument used for this research was the Rotterdam QOL questionnaire. 
We also used the Beck depression scale, and the Spielberger anxiety inventory. Our 
sample consisted of 100 patients with a confirmed diagnosis of AD from all around 
South Africa, and a control group who did not have AD or any other autoimmune 
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In 1855, in London, Thomas Addison for the first time described what is now called 
Addison's disease. This is a lifelong, chronic disease characterised by lack of cortisol 
and aldosterone which are two important steroid hormones made by the adrenal 
cortex. Cortisol mobilises nutrients in the body, modifies the body's response to 
inflammation, stimulates the liver to raise the blood sugar and helps to control the 
amount of water in the body. Aldosterone regulates salt and water levels which affect 
the blood volume and blood pressure. Cortisol production is regulated by another 
hormone, adrenocorticotrophic hormone (ACTH) which is made in the pituitary 
gland. Classical AD results from the loss of cortisol and aldosterone secretion due to 
the total or partial destruction of both the adrenal glands. This condition is also called 
primary adrenal insufficiency. Secondary adrenal insufficiency similarly causes a loss 
of cortisol secretion, but this is a distinct entity. In this case the ACTH is deficient, 
resulting in insufficient cortisol production, although aldosterone may remain 
adequate (Shomon, 2002). 
In about 70 percent of cases Addison's disease is an autoimmune condition. This 
means that the destruction is caused when the body's own immune system attacks the 
adrenal cortex as if it were a foreign body. The cortex becomes inflamed and the outer 
layer shrinks. The other 30 percent of cases are caused by infections (such as 
tuberculosis), tumours and other diseases of the glands (Shomon, 2002). 
Addison's disease symptoms 
Primary insufficiency 
The symptoms of AD do not normally appear until over 90 percent of the adrenal 
cortex has already been destroyed, so that very little adrenal capacity is left. This can 












include severe fatigue and weakness, loss of weight, increased skin pigmentation, a 
feeling of faintness, low blood pressure, nausea, vomiting, salt cravings and painful 
muscles andjoints. Because of the rather non-specific nature of these symptoms and 
their slow development, they are often missed or ignored until, for example, a 
relatively minor infection leads to an abnormally long convalescence which prompts 
an investigation. Frequently, it is not until an Addisonian crisis is precipitated that 
attention is turned to the adrenals (Colditz, 2001). 
Seconda~insuJrzcie~ 
Secondary adrenal insufficiency is sometimes described as "Addison's", although it 
has a very different cause. It typically occurs when a pituitary tumour (such as an 
adenoma) forms. The pituitary gland is a very important component of our endocrine 
system. It lies below the optic chiasm at the base of the brain. It releases hormones in 
the thyroid, adrenals and gonads. The anterior pituitary produces six hormones: 
thyroid-stimulating hormone, growth hormone, Adernocortoctropine, luteinising, 
prolactine and follicle-stimulating hormone. Pituitary active adenoma is caused by the 
disruption of the hypothalamic inhibitory hormone, dopamine, which leads to excess 
secretion of pro lac tine (Johnson and Lightman, 1996). 
In secondary adrenal insufficiency, the pituitary gland no longer triggers the adrenals 
to produce cortisol, and dehydroepiandrosterone (DHEA) production is also believed 
to decline. In most cases of secondary adrenal insufficiency, however, aldosterone is 
still produced, as its production is stimulated by other hormonal regulatory systems. 
The pituitary hormone which triggers cortisol production is called ACTH. It is 
responsible for the skin hyperpigmentation found in primary Addison's. People with 
secondary adrenal failure do not suffer the hyperpigmentation found in primary 
Addison's, because their ACTH levels are declining (Colditz, 2001). 
Long-term use of high doses of steroid drugs to treat other illnesses (for example, 
high-dose prednisone for bowel disease, emphysema or asthma) can also cause 
temporary or permanent loss of adrenal function. This is often referred to as 












Weakness and weight loss of I to IS kg are universal features of AD in adults. The 
symptoms are: nausea, vomiting, diffuse abdominal pain (present in approximately 
90 percent of patients and usually indicating an impending Addisonian crisis), 
diarrhoea (in approximately 20 percent of patients), mood disturbances (including 
depression, and irritability), and decreased concentration (Shomon, 2002). 
What is cortisol? 
Adrenal glands are located above the kidneys and nonnally produce cortisol. It 
belongs to a class ofhonnones called glucocorticoids, which affect almost every 
organ and tissue in the body. The major function and responsibility of cortisol are to 
respond to stress (Talbott, 2002). Cortisol is nonnally present in the body at higher 
levels in the morning, and is at its lowest level at night. Although stress isn't the only 
reason that cortisol is produced, it has been termed ''the stress honnone" because it is 
also secreted at higher levels during the body's "fight or flight" response to stress, and 
it is responsible for several other stress-related changes in the body (Greenberg, 
2006). 
Among its other vital tasks, cortisol helps to maintain blood pressure and 
cardiovascular function; to slow down the immune system's inflammatory response; 
to balance the effects of insulin by breaking down sugar for energy; and to regulate 
the metabolism of proteins, carbohydrates, and fats. Cortisol is involved in the 
inflammatory response, provides a quick burst of energy in survival situation, 
heightens memory functions, provides a burst of increased immunity, lowers 
sensitivity to pain, and helps maintain homeostasis in the body (Talbott, 2002). 
Although we regard cortisol as a very important honnone, it is necessary to consider 
the effects of having too high a dose of cortisol or over-replacement of cortisol. 
According to Greenberg (2006), it can have negative effects on the body; such as 
impaired cognitive perfonnance, suppressed thyroid function, blood sugar imbalances 
(for instance, hyperglycaemia), decreased bone density, decreased muscle tissue, 
higher blood pressure and lowered immunity and inflammatory responses in the body; 
another consequence, increased abdominal fat, is associated with greater health 












associated with increased stomach fat are heart attacks, strokes, the development of 
higher levels of , 'bad" cholesterol (LDL) and lower levels of "good" cholesterol 
(HDL), which can lead to further health problems. 
Guided imagery, joumaling, self-hypnosis, exercise, yoga, listening to music, 
breathing exercises and meditation are some useful methods to relax the body and 
mind that can assist the body to maintain healthy cortisol levels (Greenberg, 2006). 
Treatment of Addison's disease 
Generally, the first step in the treatment of the disease is the replacement of the 
hormones cortisol and aldosterone. Hydrocortisone, which functions like both of these 
hormones, is often a good prescription. Further treatment includes a combination of 
glucocorticoids and mineral corticoids to compensate for the adrenal insufficiency. 
Hydrocortisone and fludrocortisone are also commonly prescribed. Higher doses of 
medication are usually required during childbirth, injury, surgery, dehydration, during 
severe stress and during serious infections. During stressful events, the patient may 
develop adrenal failure which is characteristic of an Addisonian crisis in which his or 
her body is not able to produce enough cortisol. If medication is not received, a 
serious drop in blood pressure can cause shock, which may in tum prove fatal. 
Since patients with adrenal failure have lower sodium levels, it is necessary for them 
to supplement their diets with extra salt (sodium chloride), especially when weather 
conditions are hot and humid, or after heavy exercise. As AD sufferers retain 
potassium, they should avoid salt substitutes, which usually contain potassium 
chloride (Margiorios & Chrousos, 2001). 
What is quality of life? 
Quality of life (QOL) is a term that refers to people's emotional, social and physical 
wellbeing, and their ability to function in the ordinary tasks of living (Bowling, 1992). 
Factors contributing to QOL include psychological state, physical function, social 












In 1984 the World Health Organization defined health as being not only the absence 
of disease and illness but also the presence of physical, mental, and social well-being 
(Rubin, 2000). 
The importance ofQOL is explained succinctly by the Northern Centre for Healthcare 
Research (1996) when they say that "quality of life is regarded as a SUbjective report 
of the patient's experience of disease and treatment. Assessing quality of life is meant 
to enhance the insight into the consequences of the disease and its treatment, indicate 
groups of patients at risk for developing high levels of distress, and enable the 
comparison of the effectiveness of treatment and thus support decision making in 
clinical oncology." QOL has different aspects, including; psychological, physical and 
daily activity aspects (De Haes,1996). 
Physical well-being 
Physical well-being is probably the first component of health that comes to mind 
when considering QOL. According to Bowling (1992), physical well-being is defined 
in terms of a person's functional activity for which performance has been assumed to 
reflect physical health, such as self care, mobility, lack of pain or the symptoms of 
any illness and activities (e.g. walking or climbing the stairs). In addition, sleep, 
nutrition and sexual health are considered in the physical health category (Donatelle, 
2006). Accordingly, physical well-being is described when we meet the following 
terms: 
1. We are free of pain 
2. Our basic needs for food, water, sleep and shelter are met 
3. We have enough energy to accomplish our daily tasks and fulfil our recreational 
desires 
4. Our brains can maintain sufficient alertness and focus to enable our mental 
processes to function well 














Psychological well-being is a positive state of mind engendering a sense of well-being 
that enables a person to function effectively within society. Individuals who have 
good mental health are well-adjusted, are able to relate well to others, and basically 
feel satisfied with themselves and their role in society (Barry, 2002). Moods, 
thoughts, feeling, self-control and life satisfaction - feeling satisfied with what we 
have achieved in life - are necessary to measure states of psychological well-being 
(Bowling, 1992). 
In 2004 Brim, broke down the areas which contribute to psychological well-being, 
into: 
Self-acceptance: having positive thoughts about yourself; acknowledging and 
accepting multiple aspects of self; feeling positive about your past life; and being able 
to say, ''when I look at the story of my life, I am pleased with how things have turned 
out so far"(Brim, 2004). 
Personal growth: having feelings of continued development and potential and being 
open to new experiences; feeling increasingly knowledgeable and effective; and being 
able to say, "for me, life has been a continuous process of learning, changing, and 
growth." 
Purpose in life: having goals and a sense of direction in life; feeling that both present 
and past experiences are meaningful. 
Environmental mastery: feeling capable of managing a complex environment; 
choosing or creating personally appropriate contexts; and being able to say, "I am 
good at managing the responsibilities of life." 
Autonomy: being self-determining, independent, and regulating your behaviour 
internally; resisting social pressures to think and act in certain ways; evaluating 
yourself by personal standards; and being able to say, "I have confidence in my own 
opinions, even if they are different from the way most other people think." 
Positive relations with others: having warm, enjoyable, trusting relationships; being 
concerned about others' welfare and conditions; being capable of strong empathy, 
affection and intimacy; understanding the give-and-take of human relationships, and 
being able to say, "people would describe me as a giving person, willing to share my 












Activities of Dally living 
Activities of Daily Living (ADL) is one of the important components ofa QOL 
measurement as it is designed to describe, for clinical purposes, the basic tasks of 
everyday life, such as eating, bathing, dressing, toileting, transferring (walking) and 
continence (Bowling, 1992). When people are unable to perform these activities, they 
need help, either from other human beings or from mechanical devices, or both. 
Although persons of all ages may have problems performing the functions of ADL, 
the prevalence rates are much higher for the elderly. Within the elderly population, 
ADL prevalence rates rise steeply with advancing age and are especially high for 
persons aged 85 and over (Rivlin and Wiener et al, 1988). However, the ADL in this 
research does not only measure the normal daily activities such as eating, bathing, 
dressing, toileting and transferring (walking), but it also measures the daily 
performance at work (is the patient able to work according to his or her best ability?), 
and in society and social life (does the patient have the same quality of social life as 
he / she used to have?). 
Overall quality of life 
The link between physical well-being and emotions has been recognised by the 
medical field for centuries. A holistic approach called Psychoneuroimmunology 
focuses on well-being that considers body, mind and spirit in connection with illness 
and disability. According to Sheinfeld & Arnold (2006), it is well documented that 
high levels of stress can have a deleterious effect on health, well-being and the 
functioning of the immune system. Conditions ranging from depression and low self-
esteem, to nervous breakdowns and burnout, and to high levels of stress have been 
shown to undermine immune system functioning, making individuals more 
susceptible to a host of illnesses. Therefore when we assess QOL, even though we 
assess each component to see how the illness has affected it, we n~ed to have an 
overall assessment as well, because all these components are related to each other. 
The result of a complete overview on QOL and its components shows that when one 












detail. This is because one can then discern which aspect of the QOL is specifically 
impaired and needs to be improved. 
Because the treatment of AD is a lifelong course ofhonnone replacement therapy 
there have been many articles focusing on patients' QOL. ~one of these have, 
however, specifically compared the components of QOL to find out which aspect of 
QOL is more impaired in AD patients. This research argues that it is important to 
adjust patients' treatment packages according to their need and based on the South 
African context. There are of course many difficulties due to the lack of resources in 
South Africa. The result is that a large number of the patient population often cannot 
afford medical resources, especially as most of them do not have medical aid. 
Many patients are members of the casual wage system and their payment is per hour, 
making it difficult for them to take any time off work. As a result, it is difficult for 
them to consult with physicians on a regular basis. In addition, the multicultural 
nature of our society, the high rate of crime and the average South African's 
perception that society is unsafe contribute to the argument that we must adjust our 
treatment packages to patients' specific needs. The level of stress and anxiety is much 
higher than in those patients who live in European societies with lower levels of crime 
and different social stressors. This research examines two questions: first, if we get 
the same result as the European research, how do we know which aspects of QOL in 
South African and European patients with AD are more or less impaired? Second, do 
the QOL component impainnents of South African patients differ from those of 
European patients? 
Overview of psychological and clinical literature 
Cooper (1991) conducted one of the earliest studies on the relationship between 
endocrine disease and psychological distress. As he had previously documented the 
link between other autoimmune diseases and psychological problems, we decided to 
use his study as a point of departure, especially considering that we wanted to 
investigate whether the coexistence or co-morbidity of other autoimmune diseases 












Cooper emphasised the role and existence of "psychic traumas" prevalent in pituitary 
disease in his research. He concluded that patients suffering from Cushing's syndrome 
experienced stressful and uncontrollable events as significantly more "negative" and 
"independent" than his control groups. His main conclusion was that major depressive 
disorders are a severe and life-threatening complication that can occur in concurrence 
with endocrine disorders such as Cushing's syndrome, Addison's disease, 
hyperthyroidism, hypothyroidism and hyperprolactinemic amenorrhea. Other 
psychiatric symptoms, ranging from anxiety to psychotic disturbances and cognitive 
impairment may be present, though to a lesser degree than depression. 
Cooper's data show that the occurrence of an organic affective syndrome in endocrine 
disease may not simply be the consequence of increased hormonal levels, but the 
expression of a more general suprapituitary derangement. He emphasised that a 
depressed mood may have a profound influence on the AD sufferer's QOL (including 
his or her interactions with others) and on how he or she experiences the endocrine 
disease. He postulated a treatment regime primarily directed at the physical condition 
as more effective than antidepressant drugs in organic affective syndromes. This is 
supported by the effect of steroid synthesis inhibitors on depression in patients with 
Cushing's syndrome and by the action of antithyroid drugs on anxiety in patients with 
hyperthyroidism. 
When comparing the QOL components, our research results showed how our AD 
patients' treatment regime had a more significant effect on physical condition than 
psychological conditions or their daily activities. 
It is interesting to note that none of the researchers after Cooper followed his 
guidelines. In another study following this one, Cooper measured depression and the 
psychological aspect ofQOL only. This is limiting as it ignores the fact that QOL is 
also affected by physical impairment and ADL levels. 
Cooper (1991) attributed the occurrence of an organic affective syndrome in 
endocrine disease to factors other than increased hormonal levels. However, other 
researchers took a different view. Riddle et al. (1993) initiated a study into the QOL 












cortisol replacements on the perception of health and general well-being in patients 
with primary adrenocortical failure. For research purposes, they placed 14 adults 
(eight females and six males, in a randomised double-blind cross-over design) into a 
treatment experiment in which all of the patients were given three regimes of cortisol 
for one week each (regime I: 20 mg 2 times a day; regime II: 30 mg 2 times a day; 
regime III: placebo in the morning and 30mg cortisol in the evening). They then 
tracked the patients' progress over three weeks and gathered data from three 
questionnaires administered at the end of the period to assess QOL (Addison's 
questionnaire, Basler Befindlichkeits-skala and Beschwerde-liste). 
The results revealed that general well-being in terms of the patients' subjective 
contentment levels was best established during regime I in 64 percent of the patients; 
29 percent in regime II and 14 percent in regime III. The differences between regimes 
II and III were significant, and the conclusion reached was that QOL in Addison's 
patients is influenced by the dose of cortisol replacement therapy (i.e. regime I, which 
was the 20 m1 cortisol, which had a better impact on patients' QOL than regime II, 
which was 30 m1 cortisol). However, the study did not examine which aspect ofQOL 
improved most, the result being that it is difficult to determine which aspect is most 
defective. This finding is applicable to the South African context, as most South 
Africans experience generally high levels of anxiety and stress which necessitate 
different dosages of cortisol replacement therapy. A specific study would need to be 
developed, though, to get more detailed information. 
Riddle (1993) and his colleagues carried out a second study that linked the levels of 
hormones in the body to low QOL in AD patients. Their research documented the 
QOL of 80 AD patients who were on long-standing replacement therapy with 
cortisone acetate and fludrocortisone. The patients demonstrated high levels of 
impairment in terms of their physical QOL component. Specifically, they reported a 
lowered perception of their general health, decreased vitality and increased 
fatigue,with the latter suggesting a substantial lack of energy as the most prominent 
clinical problem. The authors also found significant impairment in the QOL in 
women, but the reasons for this were not clear as they had not clarified which aspects 
ofQOL were most impaired (psychological, physical or ADL levels). This 












that detail expected experiences and provide more flexibility to modify components 
when patients are in distress. 
Hunt et al (2000) undertook a similar project, focusing on the improvement in mood, 
fatigue, well-being and sexual function after DHEAS replacement in AD patients. In 
their trial, which was conducted over 12 months, they examined 106 AD patients (44 
males, 62 females) with a median age of six, using a randomised double-blind, 
parallel, placebo-controlled study. They concluded that Addison's patients are at risk 
from osteoporosis and that DHEA treatment has been shown to increase bone marrow 
disease in postmenopausal women and the aged. These parameters were measured by 
dual energy x-ray absorptiometry (DEXA) as additional major study end points. They 
concluded that a dose of 50 mg DHEA balances this deficiency, and allows for 
significant improvement in some aspects of psychological function. Using a well-
known psychometric instrument, they found significant improvement in patients' self-
esteem with a tendency toward general improvement in well-being. Their study also 
revealed significant changes in mood and fatigue after DHEA treatment. One 
commendable aspect of this research is that it considered the psychological and 
physical aspects ofQOL. However, other aspects ofQOL, such as ADL and overall 
QOL were not examined. 
Li V oon Chong et al. (200 1) questioned whether hydrocortisone replacement dosage 
could influence intraocular pressure in patients with primary and secondary 
hypocortisolism. This question is significant, as patients taking cortisol on a daily 
basis are at risk of ocular hypertension and glaucoma, which would also affect their 
general well-being and health. Li Voon Chong studied 17 patients aged 24 to 58 years 
with a mean of 42.7 years, and 20 control subjects aged 20 to 59 years, with a mean of 
38.7 years. His results showed that 
Intraocular pressures during the day are influenced by the morning 
hydrocortisone replacement dosage with significantly higher intraocular 
pressure levels in the early afternoon following 20 mg compared with 10 mg. 
A morning hydrocortisone dose of 10 mg leads to a greater physiological 
intraocular pressure profile during the day. This data supports the view that a 
daily replacement dose of 30 mg hydrocortisone may be excessive Li V oon 












Riddle (1993) and Hunt (2000) attributed low QOL to hormone replacement 
therapy, while Li Voon Chong et al. (2001) found that low QOL could be linked 
to daily doses of hydrocortisone replacement. 
Lovas (2002) also initiated a study to ascertain the correlation between the illness and 
the medication. He examined subjective reports given by 79 AD patients with 
confirmed primary adrenal failure to research the issue. As he wanted to emphasise 
the importance of fatigue, he included a separate questionnaire on this subject. He 
then compared the results of the survey with normative data from the general 
population and concluded that general health and the perception of vitality were most 
consistently impaired in patients with AD. 
Lovas also found that the scores on physical and social functioning, and physical and 
emotional roles were low in female patients. However, it must be noted that these 
results were confined to patients with autoimmune polyendocrine syndromes who 
displayed lower scores than patients with solitary AD. In this study, fatigue levels 
were higher than normal for men and women; while the working disability between 
the ages of 18 and 67 years was 26 percent, compared with 10 percent in the 
corresponding general population. This trend increased with age and was higher in 
sub-groups with concomitant endocrine diseases. Most subjective health parameters 
were lower among the disabled compared to the employed patients (Lovas, 2002). His 
study showed that female patients reported reduced physical functioning, which might 
in tum have been due to adrenal androgen depletion. Mental health seemed to have 
been more influenced by concomitant endocrine diseases, so mental fatigue might be 
a specific feature in adrenal failure. Lovas' study is limited by the fact that in 
emphasising the physical aspect ofQOL it excludes the psychological aspect and 
ADL. Overall QOL is also not examined in this study. One possibility, which needs to 
be further examined, is that psychological impairment may also have an 
interrelationship with low physical impairment conditions (such as fatigue). 
Since cortisol is a stress hormone, it can affect patients' quality of sleep, which in tum 
affects their QOL on a daily basis. According to Lovas (2003), most hormones show 
circadian variation regulated by hypothalamic pacemaker cells. Apart from the 












timing of the sleep-wake cycle has not yet been explained. Many associations have 
been described between the hypothalamic-pituitary-adrenal (HPA) axis and sleep 
architecture. The balance between growth honnone-releasing hormone (GHRH) and 
Corticotropin-releasing hormone (CRH) appears to playa key role in sleep regulation. 
CRH inhibits slow-wave sleep (SWS), which is a major component of the restorative 
non-rapid eye movement (NREM) sleep. ACTH primarily affects sleep through its 
effects on cortisol secretion. Cortisol enhances SWS possibly by the reaction 
inhibition of CRH. High levels of glucocorticoids inhibit rapid eye movement (REM) 
sleep (Lovas, 2003). However, low cortisol levels also interfere with normal REM 
sleep in patients with adrenal insufficiency. Currently, the adrenal androgen precursor 
DHEA is under scrutiny for its effects on neurons, and its possible influence on sleep 
is also being considered. To date, the predominance of sleep problems in AD sufferers 
has not been satisfactorily explained. Lovas (2003) suggests that high CRH levels, 
low cortisol levels and a reduction in DHEA levels during the night might interfere 
with physiological sleep and perhaps cause subjective sleep disturbances. 
Patients with primary adrenal failure (AD) require nonnallevels of cortisol and 
dehydroepiandrosterone. To examine this further, Lovas (2003) and his colleagues 
studied the prevalence and characteristics of perceived sleep disturbances in a large 
group of patients with AD on standard replacement therapy. They invited 60 patients 
to participate in the study and divided them into groups, comprising AD sufferers 
only, autoimmune polyendocrine syndrome type I (APS I) and autoimmune 
polyendocrine syndrome type n (APS II) for sub-group analysis. The results showed 
increased daytime fatigue, but this was not rated as higher than nonna!. This finding 
supports Li Voon Chong's research (2001). 
Stewart et af. (2004) produced a paper in which it was suggested that over-
replacement of cortisol may increase developmental delays, short stature, obesity, 
reduced bone mineral density and, arguably, premature vascular mortality in adults. 
Under-replacement of cortisol carries the risk of recurrent adrenal crises or failure of 
suppression of adrenal hyperandrogenism in patients with congenital adrenal 
hyperplasia. Such patients fail to mount an adrenocortical response to stress. Based on 
studies that defined the cortisol response to illness and surgical stress, patients were 












illnesses (such as a febrile illness) and to take hydrocortisone in doses of 100 to 200 
mg per day should they be undergoing major surgery. It is interesting to note that the 
researchers provided hardly any advice about psychological effects. Instead, they 
contended that such psychological stresses as anxiety and depression had conflicting 
results as compared with endurance exercises. This reflects the lack of an evidence 
base and confirms the need to undertake an in-depth investigation into the 
psychological distress that Addison's disease causes. 
Despite many years of study in this area, scientists still question the relationship 
between psychological distress and endocrine diseases. Sonino et al. (2004) examined 
the frequency and characteristics of psychological distress in a heterogeneous 
population of patients suffering from endocrine diseases during and after adequate 
treatment. The study was conducted on 146 patients (31 males and 1 15 females) using 
semi-structured clinical interviews to assess psychiatric (structured clinical interview 
for DSM-IV) and psychological (diagnostic criteria for psychosomatic research 
[DCPRD diagnoses. The psychosocial index, the medical outcome study short form 
and the general health survey were also used to help the patients form an idea of their 
own QOL. The results showed that 81 percent of the group presented with at least one 
psychiatric (DSM-IV) or psychological (DCPR) diagnosis. The most frequent 
diagnostic findings were generalised anxiety disorder (29 percent), major depression 
(26 percent), irritable mood (46 percent), demoralisation (34 percent) and persistent 
somatisation (21 percent). Using self-rating instruments, patients with at least one 
DSM-IV or DCPR diagnosis reported considerably more stressful lives, psychological 
distress and impaired QOL compared to those who had none. Sonino concluded that 
long term examination of endocrine patients showed a high prevalence of 
psychological distress. He further stated that thorough considerations of a patient's 
overall QOL was vital to increase therapeutic effectiveness. Sonino (2004).It can 
therefore be concluded that, in contrast to Lovas' (2002) findings, the endocrine 
patient's QOL is in fact adversely affected by the disease. 
Since 2002, more researchers have studied the effects of hormone replacement 
therapy on patients' QOL. Rose (2004) tested a hypothesis based on QOL 
assessments completed by patients with successful hormone substitution. He aimed to 












experience poor QOL or whether they recovered. He concluded that the possibilities 
available for the somatic treatments of the disease are insufficient, and that other 
psychosocial factors, such as the emotional coping strategies of patients, should be 
taken into greater account in therapy. However the aspects of QOL are not clear and 
Rose does not specify which aspects of QOL were more impaired. 
Hahner et al. (2006) produced another study that assessed the QOL in patients with 
AD. They studied 348 patients with AD and administered three standardised 
questionnaires (SF-36, GBB24, HADS) assessing their health-related QOL. They 
found that AD sufferers' QOL was significantly impaired in comparison to age- and 
gender-matched control groups from a representative random sample of the general 
population. They also noted that the failure ofDHEA to fully restore well-being 
indicates the need for further improvement of glucocorticoids replacement strategies. 
Their research also gives a very general perspective on QOL and AD patients, and has 
not specified the QOL's different aspects - the question still remains over which 
aspect ofQOL is more impaired. Do these patients suffer mainly from physical 
impairment, psychological impairment or do they have low performance in their daily 
activities? How can physicians help their patients with more details? Besides the AD 
cortisol replacement therapy what other therapies can be beneficial for them? 
According to the literature reviewed for this paper, AD has a significant impact on 
QOL, sleep and well-being. However, as most studies have been conducted in Europe, 
they would need to be further examined before they could be applied to the South 
African context. In fact, it is necessary to conduct this research as a uniquely South 
African study to determine how relevant the European studies and their treatment 
programmes are in our context. South Africa is too varied on too many levels 
compared to Europe to enable a simple comparison to be made. Psychological 
impairment in the QOL of South Africans is affected by the insecurity of having our 
personal safety constantly threatened, while our crime rate has a direct effect on our 
mental health by heightening anxiety and causing stress. Another differentiating 
factor is the lack of access to health care and medical facilities for many citizens. 
South Africa is a developing country and as such there are differences in terms of 












The literature surveyed for this paper does not explain which QOL component is 
impaired for AD patients. The question therefore arises as to whether clinicians 
should advise their patients that they will have a low general QOL or whether they 
should provide details. In order to provide more information to patients they would 
need to know which QOL component is more damaged. With this knowledge, 
physicians should be able to intervene in the early stages of the disease and raise the 
AD sufferer's QOL before it deteriorates. If, for example, they know that the patients' 
psychological component is more likely to be impaired, they would then be able to 
refer him / her for counselling to counter potentially high levels of depression and 
anxiety. Similarly, physical impairment might require physiotherapy or exercise. 
Finally, knowing further details about QOL could shed light on the possible causes of 
its decline. 
Another issue that needs further investigation concerns the fact that some patients 
have AD without any other diseases, while others have a combination of AD and 
another autoimmune system disease. The existence of other diseases in the patient 
may contribute to a reduction in psychological well-being. Such a patient would then 
need special care, such as referral to a psychologist. In this manner clinicians will gain 
insight into the underlying causes which make such patients vulnerable. 
Aims of the study 
An overview of the AD, cortisol insufficiency and QOL literature allows us to 
conclude that the impairment in QOL in patients with AD is significant. However, as 
previously mentioned, we know of no study of these symptoms in South African AD 
patients. Therefore our physicians need to know that the overall QOL of South 
African AD patients is adversely affected due to conditions in our country such as: 
• The lack of resources available to most South Africans 
• The financial effect on patients (e.g. some patients cannot afford the medication 
nor can they attend regular medical consultations to monitor the treatment 
programme) 
• Insufficient medical resources 
• The high level of crime and social insecurity 












• No access to medical aid. 
Regarding pre-existing research conducted in a European context, how similar / 
dissimilar are our results? Do we need to adjust our patients' treatment packages to 
meet their needs according to their QOL? Our research therefore aims to investigate 
the similarity between South African and European patients' QOL to determine 
whether the European findings can be applied to South Africa. The central hypothesis 
is: HI. South African patients with AD have the same QOL as European patients. 
Since QOL measures different aspects of a person's life, such as physical well-being, 
psychological well-being, daily activity and overall well-being, it is important to 
investigate in detail what the results for each component are. If we were only to report 
that these patients' QOL is low, how would we know which aspect of their quality of 
life is compromised as a result of AD or the honnone replacement therapy? In 
addition, patients with other autoimmune diseases could also have a low QOL, but 
what are the differences between the QOL assessment of each disease in the event of 
co-morbidity? Do we need to add physiotherapy to our patients' treatment packages 
or would they require psychological support such as counselling sessions to deal with 
their psychological impairment as a result of the AD? Furthermore, physicians need to 
know what the main effect of the treatment regime on their patients will most likely 
be. These questions are echoed by Rapley (2003) when he stated that QOL measures 
could serve to assist physicians in discerning amongst various treatments; to inform 
patients about the side-effects of treatment regimes; to monitor treatment efficacy 
from the patient's perspective; and to allow clinicians to better plan and coordinate 
treatment packages. 
The second topic of this study is a comparison of the various QOL components. The 
literature review shows that AD patients suffer from low QOL, but research has thus 
far failed to analyse the components ofQOL to clarify where the impairment lies. 
Patients have either been assessed physically (for example, AD and fatigue), or 
psychologically (for example, AD and depression), but in the absence of any other 
infonnation, all that we are able to discern is that AD patients have a low QOL. It is 
important for clinicians to help their patients improve their QOL, and to maintain it at 
a higher level. There are some factors of QOL that are modifiable and some that are 












treatments. So analysing the components of QOL will allow us to find out where the 
impairment lies. Therefore the second hypothesis of this study is: H2. The three 
components (physical, psychological, ADL) will not activate unifonnly. 
Finally, this study aims to compare the differences between two groups of AD 
patients. Some have a combination of AD and other autoimmune syndromes, while 
others have only AD. Generally, the former could have a lower QOL. Knowledge of 
this sort will help clinicians to design effective treatment plans. This paper contends 
that AD patients with other autoimmune diseases have a lower QOL compared to 















The minimum eligibility criterion for this study was whether patients had primary 
adrenal failure. To test our assertions, eligible subjects were enlisted from the South 
African Addison's disease database, which comprises all known Addison's disease 
patients living in South Africa. These patients have all been diagnosed with Addison's 
disease over differing periods of time. Dr Ian Ross, consultant endocrinologist, 
generated the list of patients with the assistance of other specialist physicians 
throughout South Africa. Ethical approval was granted for the 140 patients who were 
eligible for the study, and a total number of 100 patients were ultimately interviewed, 
for reasons outlined below. The subjects were interviewed telephoniCally. The 
interviewer was blind as to whether the subject was a patient or a control. 
Control group 
A matched control group was selected by identifying an individual of the same gender 
and approximate age residing in the patient's household. Additional criteria for 
selection included an assessment by the interviewer's assistant of their eligibility (e.g. 
they should not have had any earlier disease, or chronic illness), their willingness to 
give consent and their availability in terms of being present at the same time that the 
interview was conducted with patients. These individuals therefore already knew that 
an interviewer would telephone th m on a certain date at a stipulated time. 
Instruments 
Three questionnaires were administered: the Rotterdam QOL questionnaire, the Beck 
depression inventory and the Spielberger anxiety inventory: 
• Rotterdam quality of life questionnaire 
The Rotterdam QOL questionnaire was chosen as it accurately measures different 
aspects of QOL, such as physiCal, psychological, daily activity, and overall QOL that 












• Beck depression Inventory 
The Beck depression inventory (BOI) is a widely used instrument to measure mood. It 
comprises a 2l-item test presented in multiple-choice format that attempts to measure 
the presence and degree of depression in adolescents and adults. We used the 1978 
self-administered version (see appendix C). 
• Spielberger anxiety scale 
The Spielberger anxiety scale (SAS) includes 20 items, each of which has four 
answers to choose from. The questionnaire provides norms for clinical patients, high 
school and college students and working adults and it can be administered either 
individually or in a group. It differentiates clearly between the temporary condition of 
"state anxiety" and the more general and long-standing quality of "trait anxiety". It 
assists professionals in distinguishing between a client's feelings of anxiety and their 
depression. The scale's simplicity makes it ideal for evaluating individuals with lower 
educational backgrounds. The SAS has been translated into more than 40 languages 
and is the leading measure of personal anxiety worldwide (Caci et al. 2003). 
Ethics 
The study protocol was approved by the University of Cape Town's Department of 
Psychology and Groot Schuur Hospital's Ethics Board. All participants gave 
telephonic consent prior to testing, and any questions they might have had were 
answered. 
Procedures 
Initially the interviews were conducted on a face to face basis. However, three 
problems arose. The first was that skin hyperpigmentation made the patients clearly 
distinct from the controls. The second was that the patients seemed obliged to either 
downplay their symptoms or exaggerate them in face-to-face interviews. To minimise 
the interviewees' discomfort, they were asked to complete the questionnaire on paper. 
This however, did not completely eliminate the problem and also raised a new one: 
illiterate or uneducated interviewees were unable to complete the questionnaire. The 
third problem was that since patients were scattered around the country, it was not 












eliciting the most honest and unbiased answers and it was therefore decided to 
continue with data collection this way. 
The interviews were conducted between 9 a.m. and 7 p.m. Weekends were avoided. 
Interviewees were informed about the research and its aims by the co-researcher and 
were told that they would get a call on an arranged date and time for the interview. 
Respondents were then asked whether it was an appropriate time for them to answer 
the questions and whether they were still willing to participate in the study. They were 
informed that it would take only 10 to 15 minutes to conduct the interview. The 
interviewees were then asked whether they had any questions before they were 
requested to keep a pen and paper ready to write the possible answers down. For those 
who were not able to write, the options were repeated for each question. 
Each interview started with the Rotterdam QOL questionnaire, which has shorter 
questions. This was followed by the Beck questionnaire. The interviewer explained 
that the respondents should choose the option which most closely related to their 
feelings and also reminded them that if they needed to have the options repeated, as 
often as required, they should not hesitate to ask. The Spielberger questionnaire was 
then given, which again has shorter questions to avoid fatigue or boredom. At the end 
of each interview the respondents were thanked for their participation in this research. 
Groote Schuur Hospital granted ethical approval·to conduct the study on 140 
endocrine clinic outpatients. At the start of the trial, the study population was 140 
patients, but only 100 of them were available for interview. The patients and members 
of the control group were informed that a researcher, who had no knowledge of 
whether they were patients or not, would contact them. Separate questionnaires were 
used for each interviewee. All analyses were carried out using the STATISTICA 














This research attempted to answer the following questions: 
A: What is the QOL of South African AD patients, and does it differ from the QOL in 
European studies? 
B: What is the difference between the QOL components and do they affect QOL 
unifonnly? 
C: Is there a difference in the QOL of the patients who have only AD with those who 
have both AD and another autoimmune disease? 
Analysis of the data indicates that the overall QOL of South African Addison's 
disease patients is lower than the control group's overall QOL - AD patients averaged 
a score of 59.19 (sd 21.99), compared to the average score of 114.66 (sd 24.46) for 
the controls. This also indicates that, South African AD patients do not differ from 
the Europeans as well. 
Since our groups were matched and we expected the clinical group to have worse 
QOL than the control group, t-tests were used to determine group differences so one-
tailed t-tests were conducted. There was strong evidence that (p>O.OOOI) the overall 













Figure 1: Overall QOL AD patients group vs. control group 
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AD patientsl Controls 
group 
This study scrutinised the components ofQOL. Since all the scores were standardized 
from raw scores into scores on a 100 point scale in a systematic way. This made 
results more easily interpretable. Moreover, the level of quality of life impairment in 
the different scales became compared more easily. 
We investigated the differences of QOL components which were the psychological 
aspect, physical aspect, and daily activity level. This is what was missing in the 
European research. Analysis of the QOL components showed they do not affect the 
QOL uniformly. The disease had the least effect on the patients ' work performance, 
social life and daily activity level, then their psychological level, while the effect of 
the disease on their physical health was on the highest level. Reviewing the literature, 
however, gives the impression that AD patients have low QOL because they suffer 
from psychological impairments, whereas the difference between the physical 
impainnent level (average 115.82) and the psychological impainnent level (average 












Table 1: Descriptive statistic for psychological level, physical level, Daily activity 
level of AD patients' group vs. control group 












Mean 33.45 13.42 115.82 6.16 1.41 22.25 
Sd 10.11 5.34 26.19 5.26 0.64 5.69 
Bearing in mind that AD is a physical illness, it does not surprise us that patients ' 
physical complaints are greater than their psychological problems. Reviewing the 
literature gave us the impression that AD patients have psychological impairment but 
did not indicate the degree to which their psychological problems are different from 
their physical problems while they are under treatment. So our results show that, 
although AD patients suffer from psychological problems, their physical complaints 
are still more than their psychological complaints; they may alternatively be an 
indication that they have psychosomatic problems which we need to test for in future . 
Clearly the treatment packages can be improved to support the patients ' mental and 
physical health, as a result of which their daily activity level will improve as well. 
Figure 2: Quality of life impairment level in physical, psychological, daily 
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Regression was used to find out which one of the components had more impact on the 
QOL. The indication from the beta-coefficients was that physical impairment has the 
most importance. Howell (2002) suggests that the relative size of the t-values used for 
significance testing are perhaps the best for judging relative importance. By that 
standard, physical impairment (B= - 203; t= -8.6; p < .001) would be the most 
important predictor. The results show that it is primarily the physical impairment 
which causes low QOL and it is then the psychological impairment which aggravates 
theQOL. 
Since most of the previous research had found that AD patients have psychological 
damage, we decided to investigate patients' psychological impairment more closely 
by assessing their anxiety and depression separately. The results show that they have 
more or less the same levels of anxiety and depression which are higher than those of 
the control group (See Table 2). 
Table 2: Descriptive statistic 
AD patient group Control group 
Beck Spielberger anxiety Beck Spielberger anxiety 
depression inventory depression inventory 
scale scale 
Mean 34.72 35.07 23.56 21.72 
Sd 12.71 11.83 9.96 7.79 
The result of the t-test on the Beck depression scale also show that the groups differ 
(p>O.OOO), with the clinical group showing a higher level of depression than the 
control group. On the Spielberger anxiety inventory, both the groups also show 
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The last question of the research was how different is the QOL of the patients who 
only have AD from those who have both AD & another autoimmune disease? The 
results show that QOL of patients with Addison ' s disease does not differ that much 
from the patients who have AD as well as another autoimmune disease. (See Table 3) 
Table 3: Descriptive statistic 
Overall QOL clinical Overall QOL control group 
group 
Patients with AD Patients with AD and another autoimmune 
disease 
Mean 115.82 114.66 
Sd 26.19 24.45 
And finally the two groups of AD and AD with another autoimmune disease were 
compared. Since they were not a matched pair, we used the independent t-test. The 
results show that p=O.3733 and therefore patients with other autoimmune disease have 
equal levels ofQOL compared with patients with AD only. 
Figure 5: Graph box overall QOL in AD patients vs. overall QOL in AD patients 









Overall QOL measure for AD patients vs. group with other autoimmune 
disease 












The box plot of the AD group and the group of AD and another autoimmune disease 
show a high degree of overlap, which shows that their QOL impairment is very 
similar, and both have quite a high prevalence, indicating that another autoimmune 
disease does not significantly aggravate the QOL . 
The reason that we used the overall QOL separately from its components is that 
European studies have only looked at QOL in overall and in this study while we are 















Consistent with our original hypothesis, AD patients demonstrated a greater degree of 
impairment in their quality of life. A reduction in physical capabilities accounted for 
the greatest portion of this impairment, with psychological symptoms also 
contributing to the overall impairment, with psychological symptoms also 
contributing to the overall impairment, daily activity being impacted the least. AD 
patients demonstrated higher levels of both depression and anxiety, compared to 
controls. However, QOL was not different in AD patients when compared to AD 
patients comorbid autoimmune disease. 
As discussed earlier, Addison's disease is a chronic, lifelong disorder caused by 
adrenal gland insufficiency and as such it requires lifelong cortisol replacement 
therapy. For years scientists have explored the relationship between endocrine disease 
and psychological distress, with particular focus on the relationship between 
Addison's disease and the QOL of patients. They found that endocrine disease does in 
fact affect QOL and can cause depression and anxiety. They also found that different 
modes of cortisol replacement therapy affect mood and that AD sufferers frequently 
experience fatigue daily. Such sufferers also exhibit noticeably reduced worlcing 
ability and reduced health (Lovas, 2000). 
As previously stated, there is to date no study on the effect of Addison's disease on 
the QOL of patients in SA. Equally, there are no studies on which aspect ofQOL is 
affected and what QOL means for each patient. Research findings have so far only 
provided physicians with a general insight into the disease. Three important questions 
arise: 
1. How can physicians give adequate advice on the potential deleterious effects of 
AD when there is so little accurate information with which to manage their 
patients' overall convalescent needs? 
2. How can physicians know what to expect during the treatment programme they 
have prescribed to their patients when there is very little specific information 
available? 












before symptoms become worse? 
This study began in response to the need for clearer information to help answer the 
questions above. To this end, we wanted to explore the QOL of AD patients and to 
clarify the differences between its components. 
A further question that we have attempted to clarify is whether studies based on a 
European subject group would be valid and applicable in the South African context, 
given that South Africa is a developing country with a heterogonous population 
delineated along distinct economic and social lines which are different from European 
socio-political exigencies. Further differences in the subject groups are that the access 
to medical aid and health care in this country and other developing countries are 
different from those found in Europe. Such differences in health care provision leads 
to the deduction that the average South African's and European's psychological health 
differs also. The psychological health of South Africans is further exacerbated by high 
rates of crime, poverty and social insecurity. 
The last question that this study has attempted to answer is whether AD patients with 
other autoimmune diseases have worse QOL as compared to patients who only have 
AD. As the presence of other autoimmune diseases can already cause a low QOL we 
wanted to establish whether there is any difference between their QOL in comparison 
to other groups of patients who only have AD. An example would be i patient with 
Coeliac disease who, as a result of this illness, has become infertile or has had a 
miscarriage and is therefore already experiencing depression. Coeliac disease is an 
autoimmune disease that affects the intestines, and has shown a high rate of co-
morbidity with AD. 
To answer this question, we decided to assess our patients with a QOL test (the 
Rotterdam QOL questionnaire that covered the four components of QOL: 
psychological, physical, daily activity and overall QOL levels. We found the test 
suitable for gathering more information about the QOL of AD patients, allowing us to 
compare the four components of QOL and to determine which ones would be more 
affected and modifiable. To improve the accuracy of this study, we added the Beck 












In comparing our results to other research, it is necessary to have a short overview of 
the literature. In 1991 Cooper concluded that patients with endocrine disorders tend to 
suffer from various psychiatric disturbances and cognitive impainnents, specifically 
including symptoms of major depressive disorders and generalised anxiety disorders. 
Later, in 1993 he did further research concerning AD and the impact on patients of 
different doses of cortisol replacement therapy. This study produced the results 
showing that patients' QOL is adversely affected by the increased doses of cortisol. 
This information however, is too indistinct and does not allow physicians to have a 
clear understanding of the AD patients' QOL. The studies by Cooper determined that 
while psychological impairment is a factor that needs to be addressed by physicians 
treating AD patients, greater focus and attention must be placed on the physical 
impairment and its effects. While valuable, this information is incomplete as there is 
no comparative data about the other components ofQOL. The similarity between our 
research and the Cooper research is that we also found that AD patients have higher 
psychological impairment than the control group, but our study was able to show that 
patients' physical impainnent is higher than their psychological impairment. Cooper 
did not look at all the components of QOL and, as such, we are not able to make any 
comparative conclusions which might provide physicians with information on all the 
components of the QOL to determine which of these are modifiable. 
Later in 1993 Riddle and his colleagues also found that patients' general health is 
affected by the levels of cortisol in their treatment programmes. Like Cooper's, this 
study gives a vague understanding of patients' QOL and the quality of their physical 
and psychological health. The study found that the patients' general health is 
adversely affected but our research could determine in greater detail whether patients' 
physical well-being was more damaged than all other components. This study also 
showed that the patients' psychological impainnent and their daily activity level was 
higher than the control group's. The advantage of our finding was that we were able 
to determine the differences across the four components of QOL and could further 
determine the quality of each component as well as which component most aggravates 
the QOL. The similarity between Riddle's research and ours is that we also concluded 
that AD patients suffer from depression and anxiety but that is not the only reason 












impainnent level is still higher than their psychological impainnents, and that the 
difference is substantial. 
Then in 2001 Hunt et al. concluded that the self esteem and well-being of AD patients 
are hugely affected by their hormone replacement therapy. Again, we can see the 
same problem here: the information is too general; and we still do not know what the 
qualities of the components ofQOL are, and how they differ from each other. 
In 2002 Lovas found that AD patients in general experience fatigue and they have an 
impaired general health. Lovas also concluded that their physical and social 
functioning is greatly impaired. He looked at specific areas such as physical and 
social functioning, but the rest of his research still has the same approach as the earlier 
studies, giving very general information. It does not examine how other components 
are affected by AD, although, unlike other researchers, who had mainly focused on 
the psychological aspect, he looked at the physical factors. We still, therefore, need to 
look at all the other factors of QOL. However, even though his findings are focused 
on the physical aspect ofQOL, the study supports our conclusion that physical 
damage is greater than psychological and daily activity level damages. 
In 2004 Stewart et al. concluded that over-replacement of cortisol also leads to 
adverse physical health reactions, and they determined that this would lead to 
increased developmental delays, short stature, obesity, reduced bone mineral density 
and premature vascular mortality in adults. Their study focused particularly on the 
physical component of the QOL and did not look at other aspects ofQOL. This 
confirms the necessity of research which looks at every single component and 
explains exactly how each component affects a patient's QOL. Their finding does, 
however, support our conclusion that AD patients have more physical than 
psychological complaints, but that their psychological impairment is much greater 
than the control group. 
In 2004 Sonino's research was focused narrowly on psychological distress and the 
psychological component of the QOL; it proved that AD patients can suffer from a 
range of different psychological or mentiU problems. Our study can partly relate to 












looked at other components ofQOL as well. The main feature of our findings in 
comparison to Sonino's is that, while the psychological component is important, the 
patients have more physical impainnent than psychological or daily activity level 
impainnent. 
Hahner's findings in 2006 were also too vague and general. They merely concluded 
that the QOL of AD patients is impaired. This does not provide an explanation of the 
quality of each aspect of the study, nor of the components contributing to QOL. 
When we look at all the research to date we find that varying conclusions about the 
effect of AD on the psychological aspect of QOL or the physical aspect or QOL in 
general have been made. This study adopts a more holistic approach to the subject: it 
looks at all the components ofQOL and compares them with each other. Our study 
shows the comparative results for each of the QOL components, and it gives a better 
understanding to physicians and patients of the deleterious aspects of this disease and 
the effect it has on each aspect of life. 
An overview of the literature gives the strong impression that AD sufferers have low 
physical QOL but, as Riddle (1993) and his colleagues showed, the psychological 
component of the disease causes great distress too. 
Many sectors of the population dealing with AD in varying capacities can benefit 
from this research, and even more detailed studies on the overall effects of AD on 
QOL in the future. 
Within the medical population, the first group who can derive benefit from this 
research is the endocrinologists, who would gain a better understanding of the effects 
of AD on their patients' overall well-being. This infonnation allows endocrinologists 
to make a more comprehensive assessment of which component of the QOL is 
aggravated by AD, and also gives supportive evidence in advance of any changes in 
treatment packages for their patients. Of course, in order to do this most effectively 
one would need to have complete infonnation about the effect of AD on all the 












While the physical damages of AD are considerable, the psychological component of 
QOL is also affected. Therefore the second group of medical professionals who would 
benefit from the results of research discussed in this paper are psychologists. While 
endocrinologists concentrate on managing the physical aspects of this disease, the 
assistance and input of psychologists during the convalescent period are almost 
equally important. This is due to the immense psychological distress suffered by those 
patients with AD. This research has specified, through the use of the Spielberger 
anxiety test and the Beck depression test, the high frequency of anxiety and 
depression which accompanies AD, but this is a fairly two dimensional perspective on 
psychological distress which can be almost as debilitating as Addison's itself. 
Patients and their families also need to have a better knowledge and understanding 
about this disease and its symptoms. They need to know what to expect and how to 
monitor the problem. The vital information is which parts of the patient's QOL is 
most likely to be affected; what type of physical, mental and emotional assistance will 
they require; and what will be the likely effect of this disease on their overall mood 
and on their overall functioning. 
Knowing such details of the disease as are described in this study will also help 
government and medical aid companies to help patients in a more efficient way, so 
that their comprehensive needs are covered. By knowing that AD patients have a 
lower than average QOL, government and medical aid companies can measure the 
requirements of the treatment protocol for AD. This would include knowing the 
likelihood of patients needing physical and psychological support such as physical 
therapies, nutrition education, psychological counselling sessions, as well as regular 
medical check-ups with a physician qualified to monitor AD and the effects of 
cortisol, prednisone, etc on the patients. In this way, effective, comprehensive 
treatment packages could be budgeted more pragmatically and efficiently. 
Our results showed that the QOL of South African AD patients is indeed affected by 
the disease. Our patients' overall QOL impairment levels are higher than the overall 
QOL in our control group or, in other words, AD patients had much lower QOL than 
members of the control group. When reviewing all the components, and the Beck and 












lower means in comparison with the control groups. The physical impairment level 
had the highest mean compared to other components in our clinical group. The daily 
activities showed very low variability between the clinical and control groups but this 
component had the lowest impairment in both groups also. This informs us that most 
patients do not suffer with daily activity dysfunction. AB this finding demonstrates, 
the QOL in our clinical group is much lower than our control group and we can report 
with confidence that our finding is matched with what we found in the literature. We 
did not, however, stop investigating at this point since we wished to determine which 
one of the QOL components is most affected. 
As stated above, the QOL measures physical impairment, psychological impairment 
and daily activity impairment. The results of the study showed that the most affected 
component was physical, while the psychological impairment level was less affected, 
followed by the impairment in daily activity. While the frequency of physical and 
psychological impairment was quite high, the daily activity impairment was fairly 
low. From this, it can be determined that it is the physical impairment in AD patients 
which primarily causes the low QOL and that the psychological impairment is the 
second cause for their low QOL - with both of these factors needing to be taken into 
account to improve patients' QOL. 
Considering that most of the research cited gives evidence of the component 
impairment discussed in the previous paragraph, further exploration would be 
necessary to determine the exact nature of the psychological distress, to ensure that 
the physical impairment is not exacerbated by psychosomatic symptoms. 
Although Addison's disease affects patients' physical health it does not seem to have a 
significant effect on their daily activities. Their psychological impairment seems to be 
less affected than the physical components, but this does not mean that they are not 
psychologically damaged. The Beck and Spielberger inventories showed that the 
mean depression and anxiety in the clinical group is much higher than in the control 
group. It is therefore possible to assert that Addison's disease and the cortisol 
replacement therapy do indeed cause high levels of stress and anxiety. We concluded 
that the South African AD study matches its European counterpart in general, but that 












While comparing the various components we found that phySical impairment is lower 
in QOL in general, but psychological damage is found as well, and that the level of 
stress is greater than the level of depression. 
Therefore one of the modifiable factors within the QOL components is the prevalence 
of high stress and anxiety levels which can be reduced with early intervention. Such 
early intervention could include any psychological and life skills counselling, stress 
management lectures or stress control techniques such as creative art, meditation, 
relaxation and yoga, to assist patients while being treated. 
A comparison was also made between patients who had AD with the patients who had 
a combination of AD and at least one other autoimmune disease. We concluded that 
patients with AD have slightly lower QOL than patients who have AD and another 
autoimmune disease, but their overall QOL impairment is very much the same. One 
can therefore deduce that the co-morbidity of some other autoimmune disease with 
AD does not necessarily aggravate the QOL. 
Limitations of the study 
Our sample group comprised patients who had been diagnosed with AD for varying 
periods. Since the duration of the disease in our patients and their individual treatment 
programmes differed, we acknowledge that this could affect research consistency. 
Additionally, we question whether changing our interview techniques during data 
collection from personal to telephonic interviews could have had an effect on the 
accuracy of our data. Telephonic interviewing techniques are not able to determine 
the clues and congruency levels that physical characteristics such as the person's 
appearance, presentation a d expressions provide, these being important contributing 
factors in psychological assessments. 
Suggestions 
We would like to suggest that other studies include children in their research. 
Generally, children live less stressful lives than adults, mainly because they have less 












QOL. Research of this sort would be additionally valuable if it included specific 
information on how each of the QOL components is affected by AD. 
The occurrence of AD and its subsequent treatment with a cortisol replacement 
therapy or equivalent require a period of convalescence and adjustment, dming which 
additional physical therapies would be useful to alleviate the effects of cortisol 
depletion on the body. While most studies we examined specified that the component 
most affected by AD was the physical one, none specified which of the symptoms 
occurred most frequently. This infonnation would be useful, by emphasising the need 
for further research. Physicians and endocrinologists would then be able to determine 
which support therapies the patients may need in the treatment of their symptoms. For 
example, symptoms of the disease, include severe fatigue and weakness, loss of 
weight, a feeling of faintness, low blood pressure, nausea, vomiting, salt cravings and 
painful muscles and joints, indicating the need for additional physical therapies to aid 
in recovery. 
A further suggestion would be to examine a typical treatment package (as opposed to 
the disease itself) of AD using different curative strategies for stress, anxiety and 
depression. By doing this, physicians can then more accurately discern the major 
psychological malady accompanying AD, and can make recommendations to augment 
the treatment programme with particular therapies that are show to be effective. For 
example, based on a chief complaint being some fonn of generalised anxiety, a 
physician may refer a patient for cognitive behavioural therapy (CBT) and relaxation 
techniques to facilitate the improvement of their QOL. A comparative study could 
then be undertaken with AD patients who have not received CBT in their treatment 
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Rotterdam Symptom Checklist Confidential 
In this questionnaire you will be asked about your symptoms. Would you please, for 
all symptoms mentioned, indicate to what extent you have been bothered by it, by 
circling the answer most applicable to you. The questions are related to the past week. 
Example: Have you been bothered, during the past week, by headaches not at all a 
little quite a bit very much have you, during the past week, been bothered by lack of 
appetite not at all a little quite a bit very much. 
I-Irritability 
not at all a little quite a bit very much 
2-tiredness not at all a little quite a bit very much 
3-worrying not at all a little quite a bit very much 
4-sore muscles not at all a little quite a bit very much 
5-depressed mood not at all a little quite a bit very much 
6-lack of energy not at all a little quite a bit very much 
7-low back pain not at all a little quite a bit very much 
8-nervousness not at all a little quite a bit very much 
9-nausea not at all a little quite a bit very much 
IO-despairing about the future 
not at all a little quite a bit very much 
II-difficulty sleeping not at all a little quite a bit very much 
12-headaches not at all a little quite a bit very much 
13-vomiting not at all a little quite a bit very much 
14-dizziness not at all a little quite a bit very much 
15-decreased sexual interest 
not at all a little quite a bit very much 
16-tension not at all a little quite a bit very much 
17-abdominal (stomach) aches 












18-anxiety not at all a little quite a bit very much 
not at all a little quite a bit very much 
19-constipation not at all a little quite a bit very much 
20- diarrhea not at all a little quite a bit very much 
21-acid indigestion not at all a little quite a bit very much 
22-shivering not at all a little quite a bit very much 
23-tingling hands or feet 
not at all a little quite a bit very much 
24-difficulty concentrating 
not at all a little quite a bit very much 
25-sore mouth/pain when swallowing 
not at all a little quite a bit very much 
26-loss of hair 
not at all a little quite a bit very much 
27-burninglsore eyes 
not at all a little quite a bit very much 
28-shortness of breath 
not at all a little quite a bit very much 
29-dry mouth 
not at all a little quite a bit very much 
A number of activities is listed below. We do not want to know whether you 
actually do these, but only whether you are able to perform them presently. 
Would you please mark the answer that applies most to your condition of the 
past week. 
11- Unable, 2- only with without help, 3-without help, 4- with difficulty 
I-Care for myself (wash etc.) 0 0 0 0 
2-walk about the house 0 0 0 0 
3-light houseworklhousehold jobs 0 0 0 0 
4-climb stairs 0 0 0 0 












6-walk out of doors 0 0 0 0 
7-go shopping 0 0 0 0 
8-go to work 0 0 0 0 




o moderately good 
o neither good nor bad 
o rather poor 
o poor 
o extremely poor 
Would you please check whether you answered all questions? 














Beck Dwgsjon Jnventqry 
In this questionnaire aze poups of .......... ,'- read each poup of statements cazefully. 
Th~n pid.: the one statemalt in ach poup which best describes the way you have been feelina 
the Pust Week. Including Today! Citcle the ~ beside the statement you picked. If several 
stalements in the crouP seem \10 apply equally weU, cirde each one. Be lure to read all the 
statem~IUS in each ifOIIp betbse mllkiDa your choice. 
1. u. I do not foel sad. 
h. Ijet!/ sud. 
,. J UIII sad uJl o/Iite til1l#l, and I can " IN.fJI out of it. 
d I (1m so sud or uttltappy tlrar I can " fUmd ir. 
, ". 1 um nor portkularly dUcollrapd about thefoture. 
h I ji!el dis,vurGgN about tM foture. 
c. Ijed that 1 haw IIOrlring to look.forward to. 
d. l/~I!I thatlhe fotun is hopelell mtd tlrat thllflS CIl1I1IOII11tp1'Of't!. 
J " J do lIot jilellike a failure. 
,~ /./t'':/ thai I have fol1ed more lhan II" Df'f!rage person. 
L .".r I look bt.,,-k aw My Iffe, aliI can I •• Is a lot affailur.s. 
d I./'-,d I am a complet. J;lilure /IS a JMrilOn . 
.f. ,I J g"t (/l' mlldl satiljac,ion oUloftltings as IllStd to. 
f· I dOli 'tenjoy tIt/ngil the Wt{1' I Uiled to. 
I dOli " ,1(t!1 N!ai Slllis/action 0111 of afrYlhlng anymore. 
d. I </111 di.mJlisfiO'J or bond with eHrythlng. 
5. ... I dOli '1 jeel purrkuiurly guilty. 
b. Iji:d /(11111)'1/ goodparl of the 111M. 
... 1/i'1!f qUile gllilty I1Iost of the time . 
• 1. (tfel guilty all of the time. 
II. co. J .1011 'f feel I am tHing prm/shed. 
h. IfeO'/ I may be punished 
i'. J expect to be ptutlSMd 
d. Ifet!l1 am bel"g punished. 
c/. f {lOll 'r.tilel disuppaintl!d i" myself 
b. I (1m disdppointed in myself 
.. Jain disgU3tfld with myself 













· SPtelB£RGER STATE-TRAIT ANxteTY INVENTORY (STAI-S) 
DINctIena: 
A number of statements which people hwe UMd to dIIc:fIIe 1Mm ....... lIN ttv.A MIow. R4ItId 
.acr. & ... liimerli ano ",eo CirCle me apprOpn81e nUlt,oet to tn. right or tn. IUltem8l1l (0 ir.;oICCtt.: no" 
you leo! right now. tMt ii, at thie moment. There .. no right or wrong ........ Do !lOt spend too 
mud'! lime on eny one .. '-ment. ~ five !he anawer whidI I8emI to cIeKribe your ...-...nt 
feelings Mat.. 
Hetat .. ....... wMt YwylftUCtl 
I feel calm 1 2 3 .. 
-
I amtente 1 2 3 .. 
I feel upset 1 2 3 .. 
I feel frightened 1 2 3 .. 
I feel nervous 1 2 3 .. 
ram·-relaxed 1 2 3 .. 
-0-""-"-"-
'am worried 1 2 3 .. 
JI feel confused 1 2 3 .. 
l._. 
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